Cargando…
1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
BACKGROUND: Dalbavancin is an intravenous (IV) long acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections (ABSSSI). However, given the prolonged half-life, there is interest in using this agent as an alternative therapy for patients unable or unwilling to com...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752586/ http://dx.doi.org/10.1093/ofid/ofac492.1458 |